IMMU Stock Forecast: Win with a wise pick in the pharmaceutical industry

Chloe PengThe article was written by Chloe Peng, Analyst at I Know First., Master of Science of Finance candidate at Brandeis University.

Summary:

  • Though the clinical trials were influenced by the COVID-19 early this year, IMMU’s main product was approved in April by FDA, causing stock price to jump almost 30% instantly.
  • There are many opportunities facing the company, for example, the market for breast cancer drug is expanding with a growth rate of around 10%.
  • I believe the company’s revenue will triple in the next year and suggest you to buy the stock.

IMMU stock forecastRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

FMI Stock Forecast: Foundation Medicine Rallies As Acquisition Announced

 

This article was written by Julia Masch, a Financial Analyst at I Know First.

 

Highlights

  • Roche’s Acquisition of Foundation
  • The Future of Foundation
  • Current Bullish I Know First Forecast For FMI

 

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

VRX Stock Forecast: Valeant Veers Away From Scandals, Rebrands Company

 

This article was written by Julia Masch, a Financial Analyst at I Know First.

 

Summary:

  • Q1 Highlights + Product Pipeline
  • Scandals + Valeant's Valiant Name Change
  • Current I Know First Forecast For VRX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

TEVA Stock Forecast: Teva Announces Restructuring Plan After Shrank Of $57 Billion

 The article was written by Aline Rzetelna, a Financial Analyst at I Know First

TEVA Stock Prediction

Summary:

  • Why Teva Shrank By $57 billion In Two-And-A-Half Years
  • Teva Announces Restructuring Plan
  • I Know First Forecast for TEVA

Microsoft Stock OutlookRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Sarepta Stock Quick Win by the Algorithm: SRPT Remains on a Positive Trajectory

Quick Win by the Algorithm

Read The Full Forecast

Sarepta Stock

VRX Shares Quick Win by the Algorithm: A Valiant Effort to Recover

Quick Win by the Algorithm

Read The Full Forecast

Quick Win

Bullish Stocks to Buy Based on Deep Learning: Almost 24% Yield In 30 Days

Pharma Stocks ForecastPackage Name: Pharma Package
Forecast Length: 1 Month (09/05/16 – 10/05/16)
I Know First Average: 16.85%

Read The Full Forecast

Bullish Stocks to Buy

Best Pharma Stocks Based On Algorithms: Up to 15.02% Returns in 7 days

Package Name: Pharma Package
Forecast Length: 7 Days (12/15/15 – 12/23/15)
I Know First Average: 8.06%

Read The Full Forecast

Best Pharmaceutical Stocks